IDH1 and acute myeloid leukemia: This view is currently under evaluation in a clinical trial based on the administration of venetoclax and ivosidenib, with or without azacytidine in refractory/relapsed AML patients with IDH1-mutant AMLs (NCT 03471260) (Table 2).